MODULE 7: TARGET PRODUCT PROFILES
the United States Food and Drug Administration Limited use of excipients, minimum toxicity and drug interactions Excipients selected in accordance with regulatory guidelines on inactive ... pharmacopoeia as soon as possible to produce generics Equitable geographical access
Download MODULE 7: TARGET PRODUCT PROFILES
Information
Domain:
Source:
Link to this page:
Documents from same domain
INVESTING IN HEALTH FOR ECONOMIC …
www.who.int2 INVESTING IN HEALTH FOR ECONOMIC DEVELOPMENT Report by the Mexican Commission on Macroeconomics and health 3 The …
WHO GOOD PRACTICES FOR PHARMACEUTICAL …
www.who.intworking document qas/09.297/rev.2 page 2 schedule for the proposed adoption process of document qas/09.297/rev.2: who good practices for pharmaceutical microbiology laboratories
NORMES ET STANDARDS EN INFRASTRUCTURES …
www.who.intnormes et standards en infrastructures et equipements du centre de sante et de promotion sociale, du centre medical avec antenne chirurgicale et du …
Heterotrophic Plate Count Measurement in …
www.who.intWorld Health Organization Sustainable Development and Healthy Environments Heterotrophic Plate Count Measurement in Drinking Water Safety Management
Annex 3 WHO good manufacturing practices for ...
www.who.int96 Introduction The fi rst WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth
Annex 5 WHO good distribution practices for …
www.who.int236 1. Introduction Distribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are
Annex 2 WHO good practices for pharmaceutical …
www.who.int71 Introduction and scope of document Pharmaceutical microbiology laboratories may be involved in: — sterility testing; — detection, isolation, enumeration and identifi cation of microorganisms
LABORATORY BIOSAFETY MANUAL - WHO
www.who.intinterim guidelines WHO/CDS/CSR/LYO/2003.4 LABORATORY BIOSAFETY MANUAL SECOND EDITION (REVISED) WORLD HEALTH ORGANIZATION Geneva 2003
Mycobacteriology Laboratory Manual - WHO
www.who.intMycobacteriology Laboratory Manual ii Edita Pimkina, Infectious Diseases and Tuberculosis Hospital Affi liate of Public institution …
Laboratory Guidelines for enumerating CD4 T …
www.who.intSEA-HLM-392 Distribution: Limited Laboratory Guidelines for enumerating CD4 T Lymphocytes in the context of HIV/AIDS Regional Office for South-East Asia
Related documents
Medicare Benefit Policy Manual - CMS
www.cms.gov• Recognized in the official National Formulary, or the United States Pharmacopoeia, or any supplement to them, • Intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or
<88> BIOLOGICAL REACTIVITY TESTS, IN VIVO
www.drugfuture.com94 〈87〉 Biological Reactivity Tests, In Vitro / Biological Tests USP 35 (mildly reactive). Repeat the procedure if the suitability oflogical Reactivity Tests, In Vitro 〈87〉 have indicated significant the system is not confirmed. For dose-response evaluations,biological reactivity.
<1151> PHARMACEUTICAL DOSAGE FORMS
www.drugfuture.com1 In the United States a drug with a name recognized in USP–NF must comply tion—Particulate Matter in Injections 〈788〉, or mucosal—Par-with compendial identity standards or be deemed adulterated, misbranded,ticulate Matter in Ophthalmic Solutions 〈789〉). Additionally, or both. To avoid being deemed adulterated such drugs also must ...
European Medicines Agency
www.ema.europa.eufrom another pharmacopoeia as referenced in Section 2.1, in accordance with the conditions set out in this annex, as fulfilling the requirements for compliance with the Ph. Eur. Chapter 2.9.40. on the basis of the declaration of interchangeability made above.